The IL7R-Antagonist OSE-127 Blocks Acute Lymphoblastic Leukemia Development Via a Dual Mode of Action

Lennart Lenk(University Hospital Schleswig-Holstein), Denis M. Schewe(Klinik und Poliklinik für Kinder- und Jugendmedizin), Julien Taurelle(OSE Immunotherapeutics (France)), Anna Laqua(University Hospital Schleswig-Holstein), Gunnar Cario, Anna Dietterle(Christian-Albrechts-Universität zu Kiel), Nicolas Poirier(OSE Immunotherapeutics (France)), Dorothee Winterberg(Christian-Albrechts-Universität zu Kiel), Jean‐Pierre Bourquin(University Children's Hospital Zurich), Martin Schrappe(Medizinische Hochschule Hannover), Irène Baccelli(OSE Immunotherapeutics (France)), Monika Brüggemann(University Hospital Schleswig-Holstein), Fotini Vogiatzi(Christian-Albrechts-Universität zu Kiel), Beat Bornhäuser(University Children's Hospital Zurich), Emma Narbeburu(OSE Immunotherapeutics (France)), Frédérique Corallo(OSE Immunotherapeutics (France))
Blood
November 15, 2022
10.1182/blood-2022-162261
Cited by 0

Related Papers

Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: Report of the BIOMED-2 Concerted Action BMH4-CT98-3936
|Leukemia|2003|3k
Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study
|The Lancet Oncology|2014|1.3k
Outcome of Treatment in Children with Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia
|New England Journal of Medicine|2000|599
Clinical significance of minimal residual disease quantification in adult patients with standard-risk acute lymphoblastic leukemia
|Blood|2005|537
Down syndrome acute lymphoblastic leukemia, a highly heterogeneous disease in which aberrant expression of CRLF2 is associated with mutated JAK2: a report from the International BFM Study Group
|Blood|2009|347